Mild cognitive impairment

MCI - The "Uh-Oh" Moment

• Definition: A noticeable cognitive decline that is unusual for the person's age but does not interfere with Activities of Daily Living (ADLs).
• Criteria:
  • Subjective cognitive complaint from patient or informant.
  • Objective evidence of impairment (e.g., MoCA score <26).
  • Preservation of functional independence.
  • Not demented.
• Progression: High risk of progressing to dementia; rate is ~10-15% per year.

⭐ Exam Favorite: The key feature distinguishing Mild Cognitive Impairment from dementia is the preservation of independence in daily functional activities (ADLs).

MCI Subtypes - Which Way Now?

• Amnestic MCI (aMCI): Most common subtype; primary deficit is memory impairment. High risk of progressing to Alzheimer's disease.
• Non-amnestic MCI (naMCI): Impairment in non-memory domains (e.g., language, executive function, visuospatial skills).
  • Can progress to other dementias like Lewy Body, Frontotemporal, or Vascular Dementia.

⭐ The annual conversion rate from MCI to overt dementia is approximately 10-15%.

MCI Workup - Sleuthing for Clues

• Clinical & Cognitive Assessment:

  • Detailed history from patient and an informant.
  • Neurological exam to identify focal signs.
  • Cognitive screening: MoCA (preferred, score <26/30) or MMSE.
  • Formal neuropsychological testing if diagnosis is uncertain.

• Diagnostic Testing:

  • Baseline Labs: Rule out mimics (TSH, Vitamin B12, CMP, CBC).
  • Neuroimaging: Structural MRI is preferred to identify cerebrovascular disease, atrophy, or other lesions. Recommended for atypical presentations or recent onset.

⭐ High-Yield: Annual conversion rate from amnestic MCI to Alzheimer's dementia is approximately 10-15%, compared to 1-2% in the general elderly population.

MCI Management - Holding the Line

• Primary Goal: Slow progression to dementia, as there is no definitive cure.
• Non-Pharmacologic (First-Line):
  • Cognitive & Social Engagement: Brain training, new hobbies, social activities.
  • Physical Activity: Regular aerobic exercise (e.g., 150 min/week).
  • Diet: Adherence to a Mediterranean-style diet.
  • Vascular Risk Control: Aggressively manage HTN, DM, HLD.
• Pharmacologic:
  • No FDA-approved medications for MCI.
  • Cholinesterase inhibitors and memantine are not routinely recommended.
  • ⚠️ Avoid drugs with strong anticholinergic properties.
• Monitoring:
  • Regular follow-up every 6-12 months with cognitive testing.

⭐ The annual conversion rate from MCI to dementia is 10-15%, compared to 1-2% in the healthy elderly population.

High-Yield Points - ⚡ Biggest Takeaways

• MCI is a cognitive decline greater than expected for age that does not interfere with instrumental activities of daily living (ADLs).
• The most common type is amnestic MCI, primarily affecting memory.
• Diagnosis is clinical, often confirmed with neuropsychological testing.
• High risk of progression to dementia, especially Alzheimer's disease, at a rate of ~10-15% per year.
• Management involves monitoring and addressing modifiable risk factors.
• No FDA-approved medications exist to prevent progression.